Bukhman Foundation commits $12 million to T1D Fund
This support will advance cure-oriented therapies and catalyse the next wave of innovation in T1D.
The Bukhman Foundation is contributing $12 million to the T1D Fund to accelerate cure-oriented therapies and drive the next wave of innovation in T1D.
The Fund works closely with Breakthrough T1D (formerly JDRF) and the Leona M. and Harry B. Helmsley Charitable Trust , supporting research, innovation, and the global T1D community.
This milestone builds on our ongoing commitment with Diabetes UK , Breakthrough T1D, and the Bukhman Centre for Research Excellence in T1D at the University of Oxford, reflecting our dedication to collaboration and science for a future where type 1 no longer limits lives.
About the T1D Fund
Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. The Fund co-invests with venture capital and biopharma in support of early-stage companies pursuing disease modifying therapies and potential cures for T1D. A core element of our mission is to rapidly advance promising therapies through development and ultimately regulatory approval. The Fund works in close partnership with Breakthrough T1D (formerly JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust—two of the leading global organizations committed to supporting the T1D community and to advancing T1D research and innovation. Led by a deeply experienced team of healthcare and investing professionals, the Fund leverages its vast research, clinical, regulatory and medical affairs network on behalf of its portfolio companies. Capitalized through philanthropic dollars, the Fund makes investments in biotech companies and recycles returns into new investments, thereby extending the impact of its donors’ contributions.
About the Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has granted more than $4.6 billion for a wide range of charitable purposes. The Helmsley Type 1 Diabetes (T1D) Program is the largest private foundation funder in the world with a focus on T1D, with more than $1 billion to date granted to transform the trajectory of the disease and to accelerate access to 21st century care, everywhere. For more information on Helmsley and its programs, visit helmsleytrust.org .
You might also be interested in
Jenny Saville a Ca’ Pesaro
Bukhman Foundation to support the first major exhibition of the artist’s work in Venice.
Cecily Brown: Picture Making at Serpentine
Cecily Brown presents new works exploring nature, memory, and the act of painting at Serpentine, with the support of Bukhman Foundation.
Strange Evidence by Michelle Williams Gamaker
In association with the Bukhman Foundation, this new film explores Merle Oberon’s hidden heritage and pressures of early Hollywood.
